NDAORALTABLETPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENLETA (lefamulin acetate) is an oral pleuromutilin antibiotic approved in 2019 for community-acquired bacterial pneumonia (CABP). It represents a novel mechanism of action targeting bacterial protein synthesis, offering an alternative to fluoroquinolones and beta-lactams in respiratory infection treatment.
Peak6.4 years to LOE
Product is in peak commercial phase post-approval; commercial team is established but facing potential headwinds from low current competitive pressure data and limited spending visibility.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XENLETA presents career opportunities in commercial execution and market access strategy for a differentiated antibiotic in a mature, competitive indication. The peak lifecycle stage and 6+ year patent runway offer stability and growth potential, but career tenure may be limited by generic entry timeline after 2033.
Brand ManagerField Sales Representative
Worked on XENLETA at Zai Lab? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.